NFKB1 and diabetes mellitus: Inhibits synthesis of the pro-inflammatory cytokines, TNF-α and IL-6, further reducing inflammation associated with diabetes and obesity, and modulates the NF-κB signalling pathway, leading to decreased expression of inflammatory mediators